In contrast, lithium or imipramine reduced depression scores but did not improve learning.
All 18 subjects with schizophrenia were receiving an atypical antipsychotic, three were also on a typical antipsychotic, and one was also on lithium.
There was no discernible impact of treatment status on reaction time or performance, including no difference in lithium-treated versus not treated subjects.
Yet another limitation of lithium for youth with bipolar disorder is that it has a relative low safety index in overdose.
Common side effects of lithium that may be particularly problematic for children and adolescents include nausea, polyuria, polydipsia, tremor, acne, and weight gain.
As no evidence for bias has been detected good compliance is considered as potentially protective against recurrences under lithium.
As more details are discovered about the mechanisms of lithium neuroprotection, more specific hypotheses of what lithium is protecting against can be tested.
A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment.
